

ASX Release

Director Share Purchase and 3Y Release

Brisbane, Australia 24th July 2018: Oventus Medical Ltd (ASX: OVN) is pleased to release the attached 3Y notification updating Chairman Mel Bridges' holding in Oventus.

Dr Bridges said his intention was to continue to build his holding in the Company. He also stressed that the founders and directors of Oventus had no near term intentions of selling down their share in the Company despite having recently come out of escrow.

The board and executive team remain focused on commercialising its innovative technology Dr Bridges added.

-ENDS-

For more information please contact:

Dr Mel Bridges, Chairman: M: 0413051600

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O₂Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP². Oral appliances such as the Oventus range of devices have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melvyn John Bridges
Date of last notice	19 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Mel Bridges & Lucille Bridges atf The Bridges Super Fund
Date of change	20 July 2018

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: 71,778 Ordinary Shares; & 200,732 Options exercisable at \$0.578 ea; expiring 23 February 2021 Indirect – interests held by Parma Corporation Pty Ltd 1,333,186 Ordinary Shares Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 315,361 Ordinary Shares Indirect – interests held by Melvyn Bridges & Lucille Bridges as trustees for the Bridges Super Fund 458,389 Ordinary Shares Indirect – Lucille Bridges (spouse) 91,837 Ordinary Shares</p>
<p>Class</p>	<p>Ordinary Shares</p>
<p>Number acquired</p>	<p>Direct – Nil Indirect – interests held by Parma Corporation Pty Ltd Nil Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 30,600 Ordinary Shares Indirect – interests held by Melvyn Bridges & Lucille Bridges as trustees for the Bridges Super Fund 61,200 Indirect – Lucille Bridges (spouse) Nil</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust \$9,999.70 Indirect – interests held by Melvyn Bridges & Lucille Bridges as trustees for the Bridges Super Fund \$19,999.40</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	Direct: 71,778 Ordinary Shares; & 200,732 Options exercisable at \$0.578 ea; expiring 23 February 2021 Indirect – interests held by Parma Corporation Pty Ltd 1,333,186 Ordinary Shares Indirect – interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 345,961 Ordinary Shares Indirect – interests held by Melvyn Bridges & Lucille Bridges as trustees for the Bridges Super Fund 519,589 Ordinary Shares Indirect – Lucille Bridges (spouse) 91,837 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchased on market

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	19 th & 20 th July 2018

+ See chapter 19 for defined terms.